Literature DB >> 12390969

Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.

Dipankar Nandi1, Tipu Z Aziz, Nir Giladi, Jonathan Winter, John F Stein.   

Abstract

Recent studies, mainly in animals, have shown that the pedunculopontine nucleus (PPN) in the upper brainstem has extensive connections with several motor centres in the CNS. This structure has also been implicated in the akinesia seen in patients with Parkinson's disease. Here we demonstrate that microinjection of gamma-aminobutyric acid (GABA) receptor A antagonist substance, bicuculline, into the PPN of non-human primates (n = 2) rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in significant improvement of akinesia. The effect of bicuculline microinjection in the PPN matches that of oral administration of L-dopa. This finding opens up new possibilities in the management of akinesia, the most intractable symptom of advanced Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390969     DOI: 10.1093/brain/awf259

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  43 in total

Review 1.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

2.  Cholinergic and non-cholinergic mesopontine tegmental neurons projecting to the subthalamic nucleus in the rat.

Authors:  Takako Kita; Hitoshi Kita
Journal:  Eur J Neurosci       Date:  2010-12-31       Impact factor: 3.386

Review 3.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 4.  Role of the pedunculopontine nucleus in controlling gait and sleep in normal and parkinsonian monkeys.

Authors:  C Karachi; Chantal Francois
Journal:  J Neural Transm (Vienna)       Date:  2017-01-13       Impact factor: 3.575

Review 5.  Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.

Authors:  Roger L Albin; D James Surmeier; Cecilia Tubert; Martin Sarter; Martijn L T M Müller; Nicolaas I Bohnen; William T Dauer
Journal:  Mov Disord       Date:  2018-11-06       Impact factor: 10.338

6.  Commentary: the pedunculopontine nucleus: clinical experience, basic questions and future directions.

Authors:  P Mazzone; E Scarnati; E Garcia-Rill
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 7.  The pedunculopontine tegmental nucleus and experimental parkinsonism. A review.

Authors:  Masaru Matsumura
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

8.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

9.  Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.

Authors:  Jose L Lanciego; Maria C Rodríguez-Oroz; Francisco J Blesa; Lydia Alvarez-Erviti; Jorge Guridi; Pedro Barroso-Chinea; Yoland Smith; Jose A Obeso
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 10.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.